OrbiMed Advisors LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-06-24 7:15 pm Sale | 2026-06-22 | 13D | ENLIVEN THERAPEUTICS INC ELVN | OrbiMed Advisors LLC | 6,774,507 9.500% | -860,123 (-11.27%) | Filing |
| 2026-06-17 7:41 pm Sale | 2026-06-15 | 13D | ENLIVEN THERAPEUTICS INC ELVN | OrbiMed Advisors LLC | 7,634,630 10.930% | -283,533 (-3.58%) | Filing |
| 2025-06-17 5:30 pm Unchanged | 2025-06-16 | 13D | ENLIVEN THERAPEUTICS INC ELVN | OrbiMed Advisors LLC | 7,918,163 13.400% | 0 (Unchanged) | Filing |
| 2024-05-20 4:55 pm Sale | 2024-05-16 | 13D | ENLIVEN THERAPEUTICS INC ELVN | OrbiMed Advisors LLC | 7,918,163 16.800% | -1,033,300 (-11.54%) | Filing |
| 2024-04-04 4:39 pm Purchase | 2024-04-02 | 13D | ENLIVEN THERAPEUTICS INC ELVN | OrbiMed Advisors LLC | 8,951,463 19.200% | 2,124 (+0.02%) | Filing |
| 2023-02-28 4:00 pm Purchase | 2023-02-23 | 13D | ENLIVEN THERAPEUTICS INC ELVN | OrbiMed Advisors LLC | 8,949,339 21.800% | 6,416,937 (+253.39%) | Filing |